簡(jiǎn)要描述:鈣結(jié)合蛋白樣39抗體免 疫 原;KLH conjugated synthetic peptide derived from human CAB39L: 21-120/337
產(chǎn)品分類
Product Category相關(guān)文章
Related Articles詳細(xì)介紹
鈣結(jié)合蛋白樣39抗體
產(chǎn)品名稱 | 英文名稱 | 貨號(hào) |
鈣結(jié)合蛋白樣39抗體 | CAB39L | GOY-01K2828 |
商品屬性:
英文名稱: CAB39L
中文名:鈣結(jié)合蛋白樣39抗體
別 名;Antigen MLAA-34;
CAB39-LIKE PROTEIN; Cab39l; Calcium-binding protein 39-like; CB39L_HUMAN;
MO25-BETA; Mo25-like protein; MO2L; sarcoma antigen NY-SAR-79; U937-associated
antigen.
研究領(lǐng)域;腫瘤 細(xì)胞生物 信號(hào)轉(zhuǎn)導(dǎo) 腫瘤細(xì)胞生物標(biāo)志物
抗體來(lái)源;Rabbit
克隆類型;Polyclonal
交叉反應(yīng);(predicted:
Human, Mouse, Rat, Dog, Pig, Cow, Horse, Rabbit, )
產(chǎn)品應(yīng)用;WB=1:500-2000
ELISA=1:5000-10000 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500 (石蠟切片需做抗原修復(fù))
not yet tested in
other applications.
optimal dilutions/concentrations
should be determined by the end user.
理論分子量;39kDa
細(xì)胞定位;細(xì)胞漿 細(xì)胞外基質(zhì) 分泌型蛋白
性 狀;Liquid
濃 度;1mg/ml
免 疫 原;KLH
conjugated synthetic peptide derived from human CAB39L: 21-120/337
亞 型;IgG
純化方法;affinity
purified by Protein A
緩 沖 液;0.01M
TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
注意事項(xiàng);This
product as supplied is intended for research use only, not for use in human,
therapeutic or diagnostic applications.
產(chǎn)品介紹:
Peutz-Jegers Syndrome (PJS) is a rare hereditary
disease characterized by melanocytic macules of the lips, gastrointestinal
hamartomatous polyps and an increased risk for many classes of cancer.
Mutations in the gene encoding the serine/threonine kinase LKB1 (also
designated STK11) are the cause of PJS. LKB1 activity increases upon the
binding of a regulatory complex consisting of the STE20-related adaptor-α (STRAD α) pseudo kinase and
the calcium binding protein 39 (MO25, also known as CAB39). STRAD and MO25
determine the subcellular localization of LKB1 by initiating its
translocation from the nucleus to the cytoplasm, thus regulating the tumor
suppressor activity of LKB1. The LKB1/STRAD/MO25 complex acts as an
AMP-activated protein kinase kinase (AMPKK). CAB39L (calcium binding protein
39-like), also known as MO25L (MO25-like) or MO2L, is a 337 amino acid
protein that is similar to MO25 and is found in the serum of nearly half of
all patients diagnosed with acute monocytic leukemia. This suggests a role
for CAB39L in carcinogenesis. Component of a complex that binds and activates
STK11/LKB1. In the complex, required to stabilize the interaction between
CAB39/MO25 (CAB39/MO25alpha or CAB39L/MO25beta) and STK11/LKB1 (By
similarity). |
多克隆抗體制備:
我公司合成抗原,保證陽(yáng)性血清和抗體ELISA效價(jià)達(dá)到1:32000,由蛋白抗原制備的多抗,保證WB檢測(cè)結(jié)果是陽(yáng)性。技術(shù)服務(wù)實(shí)行分步報(bào)價(jià),按節(jié)點(diǎn)收費(fèi),為客戶節(jié)約成本。
鼠單克隆抗體制備:
客戶可根據(jù)項(xiàng)目實(shí)際需求情況靈活選擇進(jìn)行,我公司將為您的項(xiàng)目提供專業(yè)的建議。在制備過(guò)程中,與客戶互動(dòng)驗(yàn)證,確保最終制備的抗體ELISA陽(yáng)性血清檢測(cè)達(dá)到合同要求的同時(shí),也能滿足客戶抗體最終應(yīng)用驗(yàn)證需求。技術(shù)服務(wù)實(shí)行分步報(bào)價(jià),按節(jié)點(diǎn)收費(fèi),為客戶節(jié)約成本。
重組抗體表達(dá)服務(wù):
重組抗體技術(shù)使制備人源化抗體和人源抗體成為可能,而這是其他常規(guī)的多克隆或單克隆抗體制備方法無(wú)法做到的。我公司已搭建好的抗體測(cè)序、重組抗體表達(dá)等先進(jìn)平臺(tái),能為客戶提供各種類型的重組抗體表達(dá)服務(wù),包含鼠源單克隆抗體構(gòu)建及表達(dá)、更換恒定區(qū)亞型的嵌合抗體表達(dá),抗體人源化改造及表達(dá)等服務(wù)。
單項(xiàng)免疫學(xué)及檢測(cè)服務(wù):
我公司也為客戶提供單項(xiàng)免疫學(xué)和檢測(cè)服務(wù),如動(dòng)物免疫、動(dòng)物飼養(yǎng)、抗體修飾服務(wù)(如FITC,HRP等的標(biāo)記)、以及ELISA,WB,IHC,DB等檢測(cè)服務(wù)。
抗體定制服務(wù):
已注冊(cè)商標(biāo),主要用于抗體藥物發(fā)現(xiàn)和開發(fā),是我公司針對(duì)有特定應(yīng)用要求和各種模型測(cè)試的客戶量身定制的專業(yè)服務(wù),主要面向工業(yè)客戶。
產(chǎn)品咨詢
歡迎您關(guān)注我們的微信了解更多信息
電話
微信掃一掃